Collagen triple helix repeat containing 1 (Cthrc1) is an independently prognostic biomarker of non-small cell lung cancers with cigarette smoke

Tumor Biology

Volumn 35, Issue 11, 2014, Pages 11677-11683

  Liu, Xiaojun ^a   Liu, Beiyan ^a   Cui, Ying ^b   Wang, Fengping ^a   Sun, Hui ^a   Lv, Fuzhen ^a  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Collagen triple helix repeat containing 1; Non small cell lung cancer; Prognosis; Smoke

Indexed keywords

CTHRC1 PROTEIN, HUMAN; SCLEROPROTEIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; ADVERSE EFFECTS; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; HUMAN; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SMOKING; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SMOKING; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84927784214     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2449-0     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
2. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117:294–9.
3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.
4. Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adhes Migr. 2010;4:146–52.
5. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356:11–20.
6. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327–36.
7. O’Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: a concise review. J Clin Oncol. 2005;23:9022–8.
8. Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, et al. Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res. 2005;96:261–8.
9. Tameda M, Sugimoto K, Shiraki K, Yamamoto N, Okamoto R, Usui M, et al. Collagen triple helix repeat containing 1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation and motility. Int J Oncol. 2014;45:541–8.
10. Tang L, Dai DL, Su M, Martinka M, Li G, Zhou Y. Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res. 2006;12:3716–22.
11. Ip W, Wellman-Labadie O, Tang L, Su M, Yu R, Dutz J, et al. Collagen triple helix repeat containing 1 promotes melanoma cell adhesion and survival. J Cutan Med Surg. 2011;15:103–10.
12. Wang P, Wang YC, Chen XY, Shen ZY, Cao H, Zhang YJ, et al. CTHRC1 is upregulated by promoter demethylation and transforming growth factor-β1 and may be associated with metastasis in human gastric cancer. Cancer Sci. 2012;103:1327–33.
13. Jacques J, Hill DP, Shier KJ, Jindani A, Miller AB. Appraisal of the World Health Organization classification of lung tumours. Can Med Assoc J. 1980;122:897–901.
14. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.
15. Kharaishvili G, Cizkova M, Bouchalova K, Mgebrishvili G, Kolar Z, Bouchal J. Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study. J Clin Pathol. 2011;64:977–82.
16. Orloff M, Peterson C, He X, Ganapathi S, Heald B, Yang YR, et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA. 2011;306:410–9.
17. Park EH, Kim S, Jo JY, Kim SJ, Hwang Y, Kim JM, et al. Collagen triple helix repeat containing-1 promotes pancreatic cancer progression by regulating migration and adhesion of tumor cells. Carcinogenesis. 2013;34:694–702.
18. Li J, Zhang Z, Li G. Patient outcome prediction using multiple biomarkers in human melanoma: a clinicopathological study of 118 cases. Exp Ther Med. 2011;2:131–5.
19. Gu L, Liu L, Zhong L, Bai Y, Sui H, Wei X, et al. Cthrc1 overexpression is an independent prognostic marker in gastric cancer. Hum Pathol. 2014;45:1031–8.
20. Kim JH, Baek TH, Yim HS, Kim KH, Jeong SH, Kang HB, et al. Collagen triple helix repeat containing-1 (CTHRC1) expression in invasive ductal carcinoma of the breast: the impact on prognosis and correlation to clinicopathologic features. Pathol Oncol Res. 2013;19:731–7.
21. Tan F, Liu F, Liu H, Hu Y, Liu D, Li G. CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: a new predictor for prognosis. Med Oncol. 2013;30:473.
22. Pitule P, Vycital O, Bruha J, Novak P, Hosek P, Treska V, et al. Differential expression and prognostic role of selected genes in colorectal cancer patients. Anticancer Res. 2013;33:4855–65.
23. Chen YL, Wang TH, Hsu HC, Yuan RH, Jeng YM. Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLoS One. 2013;8:e70324.
24. Kim HC, Kim YS, Oh HW, Kim K, Oh SS, Kim JT, et al. Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells. Oncotarget. 2014;5:519–29.
25. Kelley MW. Leading Wnt down a PCP path: Cthrc1 acts as a coreceptor in the Wnt-PCP pathway. Dev Cell. 2008;15:7–8.
26. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.